<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">Many molecular diagnostic companies and institutes are devoted to developing integrated, random-access, point-of-care molecular devices for fast and accurate diagnosis of SARS-CoV-2 infection [
 <xref rid="bib6" ref-type="bibr">6</xref>]. As of 19 April 2020, the US Food and Drug Administration had approved more than 37 SARS-CoV-2 RNA detection kits (
 <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations" id="interref0010" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations</ext-link>).
</p>
